Streptase® is indicated for use in the management of acute myocardial infarction in adults.
**All products sold will be shipped within india only. product will not be shipped to international destinations. Product will only be given on Current MRP Price.
Streptokinase 1500000 IU Injection – 10 ml Vial
Price: Rs. 1,344.50
Ingredients: Streptokinase 1500000 IU
Packing: 10 ml Vial/Pack
Dosage: As directed By the Physician.
Precautions: – have recently had severe bleeding in your stomach (e.g. an ulcer) or an other stomach or intestinal disorder that causes bleeding
– have recently had a severe injury and have been resuscitated – are at risk of severe local bleeding for example if you have recently had an invasive operation (e.g. where you have had a tube or drip inserted into your body)
– have recently given birth or had a miscarriage or an abortion – have any problems in the genital area or urinary tract, especially those with bleeding.
– have had blood poisoning that could cause clotting (septic thrombotic disease)
– have a disease of the arteries or a disease affecting the blood vessels of your brain (cerebrovascular disease)
– have tuberculosis or similar lung diseases or severe bronchitis
– have any heart or circulation problems or high blood pressure
– have received any drug containing streptokinase or have had an infection caused by streptococcal bacteria such as rheumatic fever or a throat infection
– have damage to the eye caused by diabetes.
A. Early reactions: Headaches pain in the back and allergic-anaphylactic reactions with flushing and dyspnoea may occur. Allergic reactions can be largely avoided by giving the intravenous infusion slowly.
Corticosteroids can also be given prophylactically (e.g. 100 – 250 mg methylprednisolone 10 minutes before starting streptokinase treatment). If an allergic reactions occurs the infusion should be discontinued and the patient should be given corticosteroids intravenously together with adrenaline and an antihistamine.
Treatment of anaphylactic shock: Immediately inject adrenaline intravenously, but slowly. In addition give high doses of corticosteroids by slow intravenous injection, together with antihistamines and volume expanders.
B. Pyrexia, chills and rashes: Chills with or without pyrexia may occur during treatment. In most cases fever responds promptly and lastingly to antipyretics. Generalized rashes can be treated by given methylprednisolone i.v.
C. Haemorrhages: If haemorrhages occur they are usually confined to puncture sites. In such a case discontinuation of treatment is not necessary.
In serious haemorrhagic complications Streptase® therapy should be discontinued and a proteinase inhibitor, e.g. aprotinin (Trasylol) should be given
in the following dosages: Initially 200,000 K.I.U. or if necessary up to one million K.I.U., followed by 50,000 K.I.U. per hour by intravenous drip until the bleeding stops. In addition, combination with synthetic antifibrinolytics is recommended. If necessary, clotting factors can be substituted.
D. Hypotension: Streptokinase can induce hypotension when given too rapidly. The infusion should run in over a 1-hour period. (400 – 500 I.U./kg/minute)
E. Other reactions: In a few cases, neuroallergic symptoms (polyneuropathy) have been reported in temporal coincidence with Streptase® administration. In a few instances mainly after intracoronary thrombolytic therapy in patients with extensive myocardial infarctions non-cardiogenic pulmonary oedema has been observed.
The risk of pulmonary embolism in patients with deep vein thrombosis is not greater during treatment with Streptase® than during treatment with heparin alone. If acute or recurrent pulmonary embolism occurs during treatment, the course of Streptase® therapy should be continued as originally planned, so as to lyse the emboli.
Storage Conditions: Store it at room temperature and Keep away from light and children.